Executive Director
Suzanne Robotti, Founder of MedShadow Foundation Inc., entered the realm of patient advocacy driven by personal health challenges. Her mother's DES exposure in the 1950s and 1960s led Robotti to engage with DES Action, and her own struggles with infertility due to DES prompted her to advocate for others. Concerns about her son's medication side effects inspired her to delve into the impact of Ritalin. In 2014, MedShadow Foundation acquired DES Action USA, expanding its advocacy for those exposed to the harmful drug diethylstilbestrol (DES).
Editor, VOICE
Tara Haelle, a versatile freelance science and multimedia journalist, specializes in women’s health, prenatal health, vaccines, infectious disease, pediatrics, and various medical fields. A Forbes contributor, her work is featured in NPR, Scientific American, Politico, Medscape, and more. Coauthor of 'The Informed Parent,' she blogs about medical research for the Association of Health Care Journalists. Drawing on her teaching experience, Tara simplifies complex scientific ideas for diverse audiences. Holding a master’s in photojournalism from the University of Texas at Austin, her photography has been featured in regional and national publications.
